Announcement PDF Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com ASX ANNOUNCEMENT 4 November 2026 $913k Entitlement Offer Complete; Firm Commitments Received to Raise a Further $550k via Placement Melbourne, Australia; 4 November 2026: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), confirms that it has raised a total of approximately $912,962 (before costs) from its fully underwritten pro-rata renounceable entitlement offer (“Entitlement Offer”; see announcement dated 30 October 2026). Additionally, the Company has been advised by the Underwriter of the Entitlement Offer, Caravel Securities Pty Ltd ACN 655 357 915 (“Carasec”), that firm commitments have been received for a placement of approximately 55 million new, fully paid ordinary shares (“Placement Shares”) at an offer price of $0.01 per Placement Share (the same offer price as the Entitlement Offer), to raise a further ~$550,000 before costs (“Placement”). As with the Entitlement Offer, one free attaching option (“Attaching Option”) will be issued for every three Placement Shares issued. The Attaching Options will have the same terms as the Entitlement Options issued under the Entitlement Offer, including an exercise price of $0.02 and an expiry date of 3 May 2029. Carasec will act as lead manager for the Placement, and will receive a placement fee equal to 6% of the amount raised under the Placement and 6,000,000 options to acquire Shares in the Company (“Placement Fee Options”). The terms of the Placement Fee Options will be the same as the terms of the Attaching Options issued under the Placement. Commitments to participate in the Placement have been received from certain related parties of the Company (or their related entities) as follows: Dr Geoff Brooke (Non-Executive Chairman) - $25,000; Dr Kilian Kelly (Non-Executive Director) - $15,000; Mr Geoff Pocock (nominated for election as a Non-Executive Director at the Company’s forthcoming Annual General Meeting) - $20,000. The proceeds of the Placement will be used to provide the Company with greater flexibility to pursue potential transactions to secure rights to new assets, in addition to paying for the costs of the offer and providing further working capital, consistent with the use of funds outlined in the replacement Prospectus released on 12 October 2026. The Placement (including the issue of Placement Shares and Attaching Options) and the issue of the Placement Fee Options will be subject to shareholder approval, which will be sought at a General Meeting (“GM”) to be held as soon as practicable. Details of the GM will be communicated in due course. -ENDS- Authorised for release by the Board of Directors CONTACT: investors@cynata.com About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited’s (ASX: CYP) core asset is currently the Cymerus™ platform, which offers a genuinely differentiated approach to manufacturing mesenchymal stromal cells at commercial scale from a single, consistent cell source. The Board is now focused on evaluating the future development pathways available for this technology, and the broader strategic options open to the Company. This includes seeking opportunities to realise value from the Cymerus™ technology and obtaining rights to new assets. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Pty Ltd.